ClinicalTrials.gg
CompletedNCT01587989Updated Jul 17, 2015Results posted

A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

A Phase 3 interventional study of methotrexate and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 13 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-17.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
79th of 113
77 · median 130
Started
2012
with 10 others
Phase 3
47 of 113
1 open now
Registered
61st of 113
by date
Lead sponsor
28 of 113
Hoffmann-La Roche

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 79th largest by enrollment, is one of 11 that started in 2012, is one of 47 in phase 3, and was the 61st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This multicenter study with a randomized, double-blind, parallel-group phase will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in combination with methotrexate versus RoActemra/Actemra monotherapy in patients with mild to moderate rheumatoid arthritis, with an inadequate response to methotrexate. Patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks plus oral methotrexate 15-25 mg weekly for 12 weeks. Patients with a good/moderate EULAR response will then be randomized to receive either RoActemra/Actemra plus methotrexate or RoActemra/Actemra plus placebo for the following 12 weeks. Anticipated time on study treatment is 6 months.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Rheumatoid arthritis of >/= 1 year duration
  • Mild to moderate disease activity at screening (DAS 28 \</= 4.5 and >2.6)
  • On methotrexate treatment for at least 12 weeks, at stable oral dose of (10)15 mg to 25 mg/week for at least 6 weeks prior to Day 1
  • Body weight \</= 150 kg
  • Oral must have been at stable dose (maximum 10 mg/day) for at least 25 out of 28 days prior to baseline

Exclusion criteria

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after baseline
  • Rheumatic disease other than rheumatoid arthritis
  • Functional class IV American College of Rheumatology (ACR) Classification
  • Prior history of or current inflammatory joint disease other than rheumatoid arthritis
  • Treatment with a biologic agent at any time prior to baseline
  • Treatment with traditional DMARDs other than methotrexate within 1 month (for leflunomide 3 months) prior to baseline
  • Intraarticular or parenteral within 6 weeks prior to baseline
  • Previous treatment with tocilizumab
  • Pregnant or lactating women
  • Uncontrolled disease states, such as asthma, psoriasis or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids
  • Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections
  • History of or currently active primary or secondary immunodeficiency
  • Evidence of active malignant disease, diagnosed within the previous 5 years
  • Active tuberculosis requiring treatment within the previous 3 years
  • Positive for infection
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
77 participants (actual)

Study arms

  • Active comparator
    A Methotrexate

    Drug: methotrexate · Drug: tocilizumab [RoActemra/Actemra]

  • Experimental
    B Methotrexate Placebo

    Drug: methotrexate · Drug: placebo · Drug: tocilizumab [RoActemra/Actemra]

Interventions

  • 15-25 mg orally weekly, Weeks 1-12

  • 15-25 mg orally weekly, Weeks 13-24

  • Drugplacebo

    methotrexate placebo orally weekly, Weeks 13-24

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    8 mg/kg iv every 4 weeks, 24 weeks

06

What researchers measure

Primary outcomes

  1. Change From Week 12 (Randomization) to Week 24 in DAS28

    The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen joint counts (SJC) and tender joint counts (TJC), both scored 0-28 (higher scores indicate higher disease activity), as well as acute phase response (APR) determined as erythrocyte sedimentation rate (ESR), and general health (GH), both scored 1-100 (higher scores indicate higher disease activity). DAS28 was calculated according to the following formula: DAS28 equals (=) \[0.56 multiplied by (\*) the square root (√) of TJC\] plus (+) \[0.28 \* √ of SJC\] + (0.70 \* the natural logarithm (ln) ESR in millimeters per hour (mm/h)\] + \[0.014 \* GH in mm visual analogue assessment (VAS)\]. A negative change from randomization indicated improvement.

    Time frame: Weeks 12 and 24

Secondary outcomes

  1. Percentage of Participants With DAS28 Remission at Week 24

    The DAS28 is a combined index for measuring disease activity in RA. The index includes SJC and TJC, both scored 0-28 (higher scores indicate higher disease activity, as well as APR determined as ESR, and GH, both scored 1-100 (higher scores indicate higher disease activity). DAS28 was calculated according to the following formula: DAS28 = 0.56 \* √ of TJC + 0.28 \* √ of SJC + 0.70 \* ln ESR mm/hr + 0.014 \* GH in mm VAS. DAS28 \< 2.6 = remission.

    Time frame: Week 24

  2. vPercentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 24

    The CDAI is a combined index for measuring disease activity in RA. CDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), as well as patient global assessment (PGA) and evaluator global assessment (EGA) of disease activity, both scored 0 to 10 centimeter (cm) as assessed by VAS. CDAI was calculated according to the following formula: CDAI = SJC + TJC + PGA + EGA. CDAI \< 2.8 = remission.

    Time frame: Week 24

  3. Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 24

    The SDAI is a combined index for measuring disease activity in RA. SDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), PGA and EGA of disease activity, both scored 0 to 10 cm as assessed by VAS, and C-reactive protein level (CRP) in milligrams per deciliter (mg/dL) where normal \< 1 mg/dL. CDAI was calculated according to the following formula: SDAI = TJC + SJC + PGA + EGA + CRP. SDAI \< 3.3 = remission.

    Time frame: Week 24

  4. Percentage of Participants With Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5) Remission at Week 24

    The RADAI-5 is a combined index for measuring disease activity in RA. RADAI-5 is comprised of the following 5 questions: how active was your arthritis the last 6 months? (0 = completely inactive to 10 = extremely active); how active is your arthritis today with respect to joint tenderness and swelling? (0 = completely inactive to 10 = extremely active); how severe is your arthritis pain today? (0 = no pain to 10 = unbearable pain); how would you describe your general health today? (0 = very good to 10 = very bad); and did you experience joint (hand) stiffness on awakening yesterday morning? If yes, how long did this stiffness last? (0 = no stiffness to 10 = stiffness the whole day). RADAI was calculated according to the following formula: \[question (Q) 1 + Q2 + Q3 + Q4 + Q5\]/5. RADAI-5 from 0-1.4 = remission.

    Time frame: Week 24

  5. Change From Week 12 (Randomization) to Week 24 in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

    HAQ-DI scores were obtained by scoring participants' responses to a 20-item questionnaire. HAQ-DQ evaluated 8 domains of health: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities from a range of 0 (without any difficulty) to 3 (unable to do). The sum of scores was divided by the number of domains for a total score of 0 (best) to 3 (worst). A negative change from randomization indicated improvement.

    Time frame: Weeks 12 and 24

  6. Change From Week 12 (Randomization) to Week 24 in Short Form-36 Health Survey (SF-36) Score

    SF-36 scores were obtained by scoring participants' responses to a 36-item questionnaire. SF-36 evaluated 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health from a range of 1 (better) to 5 (worst). The score for each section was an average of the individual question scores, which were scaled 0-100 (100=highest level of functioning). These 8 aspects were summarized as physical and mental component scores. A negative change from randomization indicated improvement.

    Time frame: Weeks 12 and 24

  7. Change From Week 12 (Randomization) to Week 24 in Visual Analog Scales (VAS) Scores

    VAS scores were obtained by scoring participants' disease activity as assessed on a 0-100 millimeter (mm) horizontal visual scale. The left-hand extreme of the line = 0 mm (no disease activity = symptom-free and no arthritis symptoms), and the right-hand extreme of the line = 100 mm (maximum disease activity). A negative change from randomization indicated improvement.

    Time frame: Weeks 12 and 24

  8. Participant Satisfaction With Treatment as Assessed by Treatment Satisfaction Questionnaire for Medication (TSQM) Score

    TSQM scores were obtained by scoring participants' responses to a 14-item questionnaire. TSQM evaluated 4 aspects of treatment satisfaction: effectiveness, side effects, convenience, and global satisfaction from a range of 0 to 100 percent (%), with 100% being the best possible result.

    Time frame: Week 24

07

Results

Posted Jul 17, 2015

Participant flow

12-Week Open-Label Run-In Period
Participant flow — 12-Week Open-Label Run-In Period
MilestoneAll ParticipantsGroup A: TCZ + MTXGroup B: TCZ + Placebo
Started7700
Completed6500
Not completed1200
Withdrew: Physician decision700
Withdrew: Withdrawal by subject100
Withdrew: No eular response400
Randomized Study Treatment
Participant flow — Randomized Study Treatment
MilestoneAll ParticipantsGroup A: TCZ + MTXGroup B: TCZ + Placebo
Started03233
Completed03032
Not completed021
Withdrew: Withdrawal by subject010
Withdrew: Screening failure010
Withdrew: Physician decision001

Outcome measures

PrimaryChange From Week 12 (Randomization) to Week 24 in DAS28

The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen joint counts (SJC) and tender joint counts (TJC), both scored 0-28 (higher scores indicate higher disease activity), as well as acute phase response (APR) determined as erythrocyte sedimentation rate (ESR), and general health (GH), both scored 1-100 (higher scores indicate higher disease activity). DAS28 was calculated according to the following formula: DAS28 equals (=) \[0.56 multiplied by (\*) the square root (√) of TJC\] plus (+) \[0.28 \* √ of SJC\] + (0.70 \* the natural logarithm (ln) ESR in millimeters per hour (mm/h)\] + \[0.014 \* GH in mm visual analogue assessment (VAS)\]. A negative change from randomization indicated improvement.

Time frame:
Weeks 12 and 24
Reported as:
Mean · score on a scale
Change From Week 12 (Randomization) to Week 24 in DAS28
score on a scaleGroup A: TCZ + MTXGroup B: TCZ + Placebo
Change From Week 12 (Randomization) to Week 24 in DAS280.17 ± 0.83-0.16 ± 1.13
Statistical analysis
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · t-test, 2 sided · p = 0.188 · Mean difference (final values): 0.327 · 95% CI -0.165 to 0.820
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · ANCOVA · p = 0.015
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · ANCOVA · p = 0.304
SecondaryPercentage of Participants With DAS28 Remission at Week 24

The DAS28 is a combined index for measuring disease activity in RA. The index includes SJC and TJC, both scored 0-28 (higher scores indicate higher disease activity, as well as APR determined as ESR, and GH, both scored 1-100 (higher scores indicate higher disease activity). DAS28 was calculated according to the following formula: DAS28 = 0.56 \* √ of TJC + 0.28 \* √ of SJC + 0.70 \* ln ESR mm/hr + 0.014 \* GH in mm VAS. DAS28 \< 2.6 = remission.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28 Remission at Week 24
percentage of participantsGroup A: TCZ + MTXGroup B: TCZ + Placebo
Percentage of Participants With DAS28 Remission at Week 2481.2587.50
Statistical analysis
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · Fisher Exact · p = 0.732
SecondaryvPercentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 24

The CDAI is a combined index for measuring disease activity in RA. CDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), as well as patient global assessment (PGA) and evaluator global assessment (EGA) of disease activity, both scored 0 to 10 centimeter (cm) as assessed by VAS. CDAI was calculated according to the following formula: CDAI = SJC + TJC + PGA + EGA. CDAI \< 2.8 = remission.

Time frame:
Week 24
Reported as:
Number · percentage of participants
vPercentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 24
percentage of participantsGroup A: TCZ + MTXGroup B: TCZ + Placebo
vPercentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 2434.3853.13
Statistical analysis
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · Fisher Exact · p = 0.207
SecondaryPercentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 24

The SDAI is a combined index for measuring disease activity in RA. SDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), PGA and EGA of disease activity, both scored 0 to 10 cm as assessed by VAS, and C-reactive protein level (CRP) in milligrams per deciliter (mg/dL) where normal \< 1 mg/dL. CDAI was calculated according to the following formula: SDAI = TJC + SJC + PGA + EGA + CRP. SDAI \< 3.3 = remission.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 24
percentage of participantsGroup A: TCZ + MTXGroup B: TCZ + Placebo
Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 2440.6353.13
Statistical analysis
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · Fisher Exact · p = 0.453
SecondaryPercentage of Participants With Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5) Remission at Week 24

The RADAI-5 is a combined index for measuring disease activity in RA. RADAI-5 is comprised of the following 5 questions: how active was your arthritis the last 6 months? (0 = completely inactive to 10 = extremely active); how active is your arthritis today with respect to joint tenderness and swelling? (0 = completely inactive to 10 = extremely active); how severe is your arthritis pain today? (0 = no pain to 10 = unbearable pain); how would you describe your general health today? (0 = very good to 10 = very bad); and did you experience joint (hand) stiffness on awakening yesterday morning? If yes, how long did this stiffness last? (0 = no stiffness to 10 = stiffness the whole day). RADAI was calculated according to the following formula: \[question (Q) 1 + Q2 + Q3 + Q4 + Q5\]/5. RADAI-5 from 0-1.4 = remission.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5) Remission at Week 24
percentage of participantsGroup A: TCZ + MTXGroup B: TCZ + Placebo
Percentage of Participants With Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5) Remission at Week 2432.2654.55
Statistical analysis
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · Fisher Exact · p = 0.084
SecondaryChange From Week 12 (Randomization) to Week 24 in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

HAQ-DI scores were obtained by scoring participants' responses to a 20-item questionnaire. HAQ-DQ evaluated 8 domains of health: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities from a range of 0 (without any difficulty) to 3 (unable to do). The sum of scores was divided by the number of domains for a total score of 0 (best) to 3 (worst). A negative change from randomization indicated improvement.

Time frame:
Weeks 12 and 24
Reported as:
Mean · score on a scale
Change From Week 12 (Randomization) to Week 24 in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
score on a scaleGroup A: TCZ + MTXGroup B: TCZ + Placebo
Change From Week 12 (Randomization) to Week 24 in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score0.04 ± 0.28-0.06 ± 0.40
Statistical analysis
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · Wilcoxon (Mann-Whitney) · p = 0.842
SecondaryChange From Week 12 (Randomization) to Week 24 in Short Form-36 Health Survey (SF-36) Score

SF-36 scores were obtained by scoring participants' responses to a 36-item questionnaire. SF-36 evaluated 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health from a range of 1 (better) to 5 (worst). The score for each section was an average of the individual question scores, which were scaled 0-100 (100=highest level of functioning). These 8 aspects were summarized as physical and mental component scores. A negative change from randomization indicated improvement.

Time frame:
Weeks 12 and 24
Reported as:
Mean · score on a scale
Change From Week 12 (Randomization) to Week 24 in Short Form-36 Health Survey (SF-36) Score
score on a scaleGroup A: TCZ + MTXGroup B: TCZ + Placebo
Physical standardized value0.89 ± 10.480.75 ± 10.08
Mental standardized value-5.41 ± 9.24-1.69 ± 9.20
Statistical analysis
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · Wilcoxon (Mann-Whitney) · p = 0.417
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · Wilcoxon (Mann-Whitney) · p = 0.112
SecondaryChange From Week 12 (Randomization) to Week 24 in Visual Analog Scales (VAS) Scores

VAS scores were obtained by scoring participants' disease activity as assessed on a 0-100 millimeter (mm) horizontal visual scale. The left-hand extreme of the line = 0 mm (no disease activity = symptom-free and no arthritis symptoms), and the right-hand extreme of the line = 100 mm (maximum disease activity). A negative change from randomization indicated improvement.

Time frame:
Weeks 12 and 24
Reported as:
Mean · score on a scale
Change From Week 12 (Randomization) to Week 24 in Visual Analog Scales (VAS) Scores
score on a scaleGroup A: TCZ + MTXGroup B: TCZ + Placebo
Fatigue1.91 ± 17.16-1.88 ± 17.49
Pain1.09 ± 18.48-2.88 ± 22.04
Statistical analysis
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · Wilcoxon (Mann-Whitney) · p = 0.655
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · Wilcoxon (Mann-Whitney) · p = 0.839
SecondaryParticipant Satisfaction With Treatment as Assessed by Treatment Satisfaction Questionnaire for Medication (TSQM) Score

TSQM scores were obtained by scoring participants' responses to a 14-item questionnaire. TSQM evaluated 4 aspects of treatment satisfaction: effectiveness, side effects, convenience, and global satisfaction from a range of 0 to 100 percent (%), with 100% being the best possible result.

Time frame:
Week 24
Reported as:
Mean · score on a scale
Participant Satisfaction With Treatment as Assessed by Treatment Satisfaction Questionnaire for Medication (TSQM) Score
score on a scaleGroup A: TCZ + MTXGroup B: TCZ + Placebo
Effectiveness72.41 ± 34.8582.49 ± 24.14
Side-effects94.15 ± 19.1694.89 ± 14.70
Convenience85.48 ± 21.9786.03 ± 15.60
Global satisfaction86.64 ± 21.0986.36 ± 13.53
Statistical analysis
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · Wilcoxon (Mann-Whitney) · p = 0.580
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · Wilcoxon (Mann-Whitney) · p = 0.975
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · Wilcoxon (Mann-Whitney) · p = 0.421
  • Group A: TCZ + MTX vs Group B: TCZ + Placebo · Wilcoxon (Mann-Whitney) · p = 0.277

Adverse events

Collected over Adverse events (AEs) were collected from Weeks 12-24.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A: TCZ + MTX—2/32 (6.3%)14/32 (43.8%)
Group B: TCZ + Placebo—5/33 (15.2%)12/33 (36.4%)
Most frequent serious events
Most frequent serious events
EventGroup A: TCZ + MTXGroup B: TCZ + Placebo
Alanine aminotransferase increasedInvestigations1/320/33
Cerebrovascular accidentNervous system disorders1/320/33
Joint effusionMusculoskeletal and connective tissue disorders0/321/33
Urinary tract infectionInfections and infestations0/321/33
LacerationInjury, poisoning and procedural complications0/321/33
Meniscus injuryInjury, poisoning and procedural complications0/321/33
GastritisGastrointestinal disorders0/321/33
Most frequent other events
Most frequent other events
EventGroup A: TCZ + MTXGroup B: TCZ + Placebo
LeukopeniaBlood and lymphatic system disorders5/322/33
NasopharyngitisInfections and infestations5/321/33
NauseaGastrointestinal disorders3/325/33
Oral herpesInfections and infestations1/325/33
Alanine aminotransferase increasedInvestigations4/325/33
Aspartate aminotransferase increasedInvestigations3/324/33

Baseline characteristics

Intent to treat (ITT) population: all randomized participants who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)Group A: TCZ + MTXGroup B: TCZ + PlaceboTotal
Mean57.78 ± 11.8857.15 ± 10.8357.46 ± 11.28
Sex: Female, Male
Sex: Female, Male(Participants)Group A: TCZ + MTXGroup B: TCZ + PlaceboTotal
Female262551
Male6814
08

Study locations

13 sites
  • Graz-Eggenberg, 8020, Austria
  • Graz, 8036, Austria
  • Hollabrunn, 2020, Austria
  • Innsbruck, 6020, Austria
  • Linz, 4020, Austria
  • Salzburg, 5020, Austria
  • Stockerau, 2000, Austria
  • Wels, 4600, Austria
  • Wien, 1090, Austria
  • Wien, 1100, Austria
  • Wien, 1130, Austria
  • Wien, 1140, Austria
  • Wien, 1160, Austria
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2012
First posted
Apr 30, 2012
Start
Feb 2012
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Jul 17, 2015
Last update
Jul 17, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01587989
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 30, 2012
Start date
Feb 2012
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Jul 17, 2015
Last update
Jul 17, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Tocilizumab

Start the discussion